AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01844128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: weight loss
Study NCT01708629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered SC
Study NCT05810558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glycine powder air-powered debridement
Description: The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
Study NCT05810558 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic instrumentation
Description: The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
Study NCT03939299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT
Description: Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
Study NCT04054505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EZPAK
Description: One packet with breakfast for three months
Study NCT01418482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border Ag
Description: a silver dressing
Study NCT00551096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
Study NCT00551096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
Study NCT00551096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
Study NCT04054505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One packet with breakfast for three months
Study NCT01374997 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: micromethod from samples taken from blood spots on filter paper
Description: a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
Study NCT03954665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 km time trial
Description: 10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
Study NCT03954665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30s Wingate
Description: 30s all-out test to measure peak power output
Study NCT03954665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: Supplement containing exogenous ketone salts
Study NCT03954665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline 10 km time trial
Description: A baseline 10 km Cycling time trial test will be conducted
Study NCT03954665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline 30s Wingate
Description: A baseline 30s all-out test to measure peak power output
Study NCT04338074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
Study NCT04338074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 2 tablets p.o. three times per day x 5 days
Study NCT02185092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: probiotic supplement
Study NCT02185092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: placebo
Study NCT04803071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group of n-pufas improving cognitive formula
Description: Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
Study NCT04803071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: General fish oil formula product adjuvant treatment control group
Description: The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
Study NCT04803071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo assisted treatment group
Description: Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
Study NCT02133469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)
Description: injection 0.5 mL, single dose
Study NCT02133469 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib Vaccine
Description: Single Dose
Study NCT01132352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study NCT01132352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study NCT02402595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923
Study NCT01930864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin up to 2500mg/d
Study NCT01930864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan 350 mg/m² IV q21d
Study NCT00925041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vedera KXS
Description: one treatment with the Vedera KXS
Study NCT02402595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Study NCT02402595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT00939770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT00939770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00939770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00939770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01450995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
Study NCT01450995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex and two Aleve
Description: Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
Study NCT03931161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab Auto-Injector [Repatha]
Description: Auto-Injector, 140 mg every two weeks.
Study NCT03931161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Auto-Injector
Description: Matching Placebo for the active comparator (Evolocumab)
Study NCT04066023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C213 Microneedle System
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
Study NCT04066023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
Study NCT01552694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral, 100 mg/day for 2 months
Study NCT01552694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, matching placebo daily for 2 months
Study NCT01211730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
Study NCT01752361 — intervention group
Intervention type: DEVICE
Intervention: Motilis-3D transit
Study NCT02178371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mCIMT
Description: affected upper limb use with constraint of the healthy hand
Study NCT02178371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unimanual therapy without constraint UTWC
Description: affected upper limb use without constraint of healthy hand
Study NCT00758836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00758836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Study NCT00758836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen
Study NCT00758836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: telcagepant
Study NCT00758836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant
Study NCT03668860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg/ml
Description: Intramuscular. Total dose: 1.5 mL (6 mg)
Study NCT03668860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 4 mg/ml
Description: Intramuscular. Total dose: 1.5 mL (6 mg)
Study NCT03668860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone Soluspan 6Mg/Ml Suspension for Injection
Description: Intramuscular. Total dose: 1 mL (6 mg)
Study NCT03668860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)
Study NCT03668860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)
Study NCT00816595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00816595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously
Study NCT00816595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00816595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00816595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Description: Given IV
Study NCT02378259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
Study NCT02378259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intense conservative treatment
Description: Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
Study NCT03815136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will not chew chewing gum while undergoing capsule endoscopy
Study NCT02343029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised aerobic exercise training
Description: During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
Study NCT02343029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualised aerobic exercise training
Description: During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
Study NCT02343029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting Control
Description: After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
Study NCT01275287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients > than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir > 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study.
Study NCT01275287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
Study NCT04295915 — intervention group
Intervention type: DEVICE
Intervention: Specimens that meet inclusion criteria
Description: Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
Study NCT03825978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal Genetic Counseling
Description: In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
Study NCT02795052 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravenous and Intranasal BMSC
Description: Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
Study NCT03406936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily interruption of midazolam
Description: daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
Study NCT01622868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01622868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT01622868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT01622868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study NCT00803387 — intervention group
Intervention type: DRUG
Intervention: Travaprost without BAC (Travatan Z)
Description: A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
Study NCT00654589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT03423407 — intervention group
Intervention type: DEVICE
Intervention: Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Description: FDA approved scanner
Study NCT03303651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid administration in intervention groups
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
Study NCT03303651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid administration in control group
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
Study NCT01544855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
Study NCT01285986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein collar at the distal anastomosis
Description: Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
Study NCT00672594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
Study NCT03500211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm 5 % Topical Patch
Description: Lidocaine patch after cesarean section delivery.
Study NCT03500211 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Topical Patch
Description: Sham patch after cesarean section delivery.
Study NCT00059631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (Novantrone)
Description: Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
Study NCT00059631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (PS-341)
Description: Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
Study NCT04093687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopist's training
Description: The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator.
Study NCT00649818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam Tablets 2 mg
Description: 2mg, single dose fasting
Study NCT00649818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ativan Tablets 2 mg
Description: 2mg, single dose fasting
Study NCT01554826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Split Vaccine
Description: 0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart